Last checked at 3 Mar 2022 09:55
3 March 2022
Scancell Holdings plc
("Scancell" or the "Company")
Director Dealing
Scancell (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious diseases, announces that Vulpes Life Science Fund, a person closely associated with Martin Diggle, Non-Executive Director of the Company, has purchased 250,000 ordinary shares of 0.1 pence each ("Ordinary Shares") in the Company on 2 March 2022 at a price of 12 pence per share. Following the purchase, Vulpes Life Science Fund holds 117,729,029 Ordinary Shares representing 14.4% of the Company's issued share captial.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Vulpes Life Science Fund |
2 | Reason for the notification | |
a) | Position/status | Person closely associated with Martin Diggle, Non-Executive Director |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Scancell Holdings plc |
b) | LEI | 2138008RXEG856SNP666 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.1 pence each |
b) | Identification Code | GB00B63D3314 |
c) | Nature of the transaction | Purchase of Ordinary Shares |
d) | Price(s) and volume(s) | 250,000 Ordinary Shares 12 pence per Ordinary Share |
e) | Aggregated information - Aggregated volume - Price |
N/A (single transaction)
|
f) | Date of the transaction | 2 March 2022 |
g) | Place of the transaction | London Stock Exchange, AIM |
- ENDS -
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).
For more information, please contact:
For further information, please contact: | |
Scancell Holdings plc | +44 (0) 20 3727 1000 |
Dr John Chiplin, Executive Chairman | |
Professor Lindy Durrant, CEO | |
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7886 2500 |
Freddy Crossley / Emma Earl (Corporate Finance) | |
Rupert Dearden (Corporate Broking) | |
Stifel Nicolaus Europe Limited (Joint Broker) | +44 (0) 20 7710 7600 |
Nicholas Moore / Samira Essebiyea / William Palme-Brown (Healthcare Investment Banking) | |
Nick Adams / Nick Harland (Corporate Broking) | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Rob Winder / Alex Davis |
Notes for Editors
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with four products in multiple cancer indications and development of a vaccine for COVID-19.
ImmunoBody® vaccines target dendritic cells and stimulate both CD4 and CD8 T cells with the ability to identify, target and eliminate cancer cells. These cancer vaccines have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. The Directors believe that this platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
DNA vaccine against COVID-19: As research data emerges, it is becoming increasingly clear that the induction of potent and activated T cells may play a critical role in the development of long-term immunity and clearance of virus-infected cells. Initial research is underway and Scancell has initiated a Phase 1 clinical trial known as COVIDITY in October 2021. The COVIDITY programme, which has received funding from Innovate UK. is a collaboration between Scancell and scientists in the newly established Centre for Research on Global Virus Infections and the new Biodiscovery Institute at the University of Nottingham, and Nottingham Trent University.
Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). Examples of such modifications are citrullination, an enzyme-based conversion of arginine to citrulline, and homocitrullination (or carbamylation), in which lysine residues are converted to homocitrulline. Expression of peptides containing these modifications have been demonstrated to induce potent CD4 cytotoxic T cells to eliminate cancer. The Directors believe that this platform has the potential to eradicate hard to treat solid tumours.
AvidiMab™ has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody (mAb) including those being developed for autoimmune diseases, as well as cancer. Scancell's development pipeline includes mAbs against specific tumour-associated glycans (TaGs) with superior affinity and selectivity profiles, that have now been further engineered using the Company's AvidiMab™ technology; this confers the Scancell anti-TaG mAbs with the ability to directly kill tumour cells. The mAbs targeting TaGs can also be used to deliver cytotoxic payload to cancer or to redirect T cells.